3 unchanged sentences
Holders of Ordinary Shares
−Removed: As of February 16, 2021, there were three holders of record of our ordinary shares.
+Added: As of February 22, 2022, there were 907 holders of record of our ordinary shares.
Because almost all of our ordinary shares are held by brokers, nominees and other institutions on behalf of shareholders, we are unable to estimate the total number of shareholders represented by these record holders.
14 unchanged sentences
In addition, dividends or payments on redemption or purchase of shares and payments on a liquidation of an Irish incorporated company would fall within this definition.
−Removed: At present the Financial Transfers Act, 1992 prohibits financial transfers involving the late Slobodan Milosevic and associated persons, Belarus, certain persons indicted by the International Criminal Tribunal for the former Yugoslavia, the late Osama bin Laden, Al-Qaida, the Taliban of Afghanistan, Democratic Republic of Congo, Democratic People’s Republic of Korea (North Korea), Iran, Iraq, Côte d’Ivoire, Lebanon, Liberia, Zimbabwe, Sudan, Somalia, Republic of Guinea, Republic of Guinea-Bissau, Afghanistan, Egypt, Libya, Syria, Tunisia, certain known terrorists and terrorist groups, countries that harbor certain terrorist groups and Ukraine without the prior permission of the Central Bank of Ireland.
+Added: At present the Financial Transfers Act, 1992 prohibits financial transfers involving the late Slobodan Milosevic and associated persons, Belarus, certain persons indicted by the International Criminal Tribunal for the former Yugoslavia, the late Osama bin Laden, Al-Qaida, the Taliban of Afghanistan, Democratic Republic of Congo, Democratic People’s Republic of Korea (North Korea), Iran, Iraq, Côte d’Ivoire, Lebanon, Liberia, Zimbabwe, Sudan, Somalia, Republic of Guinea, Republic of Guinea-Bissau, Afghanistan, Libya, Syria, Tunisia, certain known terrorists and terrorist groups, countries that harbor certain terrorist groups and Ukraine without the prior permission of the Central Bank of Ireland.
Any transfer of, or payment in respect of, a share or interest in a share involving the government of any country that is currently the subject of United Nations sanctions, any person or body controlled by any of the foregoing, or by any person acting on behalf of the foregoing, may be subject to restrictions pursuant to such sanctions as implemented into Irish law.
21 unchanged sentences
Performance Measurement Comparison (1)
−Removed: The following graph shows the total shareholder return on the last day of each year of an investment of $100 in cash as if made on December 31, 2015 in (i) our ordinary shares;
+Added: The following graphs show the total shareholder return on the last day of each year of an investment of $100 in cash as if made on December 31, 2016 and December 31, 2011, respectively, in (i) our ordinary shares;
(ii) the Nasdaq Composite Index;
and (iii) the Nasdaq Biotechnology Index through December 31, 2021.
−Removed: The shareholder return shown in the graph below is not necessarily indicative of future performance, and we do not make or end orse any predicti ons as to future shareholder returns.
+Added: The shareholder return shown in the graphs below are not necessarily indicative of future performance, and we do not make or end orse any predicti ons as to future shareholder returns.
COMPARISON OF FIVE YEAR CUMULATIVE TOTAL RETURN (2)
+Added: COMPARISON OF TEN YEAR CUMULATIVE TOTAL RETURN (2)
_________________________
4 unchanged sentences
Under this program, which has no expiration date, we may repurchase ordinary shares from time to time on the open market.
−Removed: During the three months ended December 31, 2020, we did not repurchase any of our ordinary shares.
−Removed: In 2020, we spent a total of $146.5 million to purchase 1.2 million of our ordinary shares under the share repurchase program at an average total purchase price, including commissions, of $121.98 per share.
−Removed: All ordinary shares repurchased were canceled.
+Added: In 2021, we did not repurchase any of our ordinary shares under the share repurchase program.
As of December 31, 2021, the remaining amount authorized under the share repurchase program was $431.2 million.
−Removed: Selected Financial Data
−Removed: The following selected consolidated financial data should be read together with our consolidated financial statements and accompanying notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” appearing elsewhere in this Annual Report on Form 10‑K.
−Removed: The selected consolidated financial data in this section is not intended to replace our consolidated financial statements and the accompanying notes.
−Removed: Our historical results are not necessarily indicative of our future results.
−Removed: We derived the consolidated statements of income data for the years ended December 31, 2020, 2019 and 2018 and the selected consolidated balance sheet data as of December 31, 2020 and 2019 from the audited consolidated financial statements appearing elsewhere in this Annual Report on Form 10‑K.
−Removed: The consolidated statements of income data for the years ended December 31, 2017 and 2016, and the selected consolidated balance sheet data as of December 31, 2018, 2017 and 2016 are derived from audited consolidated financial statements not included in this Annual Report on Form 10‑K.
−Removed: Year Ended December 31,
−Removed: 2020 2019 2018 2017 2016(1)
−Removed: (In thousands, except per share amounts)
−Removed: Consolidated Statements of Income Data:
−Removed: Product sales, net $ 2,346,660 $ 2,135,601 $ 1,869,473 $ 1,601,399 $ 1,477,261
−Removed: Royalties and contract revenues 16,907 26,160 21,449 17,294 10,712
−Removed: Total revenues 2,363,567 2,161,761 1,890,922 1,618,693 1,487,973
−Removed: Operating expenses:
−Removed: Cost of product sales (excluding amortization of acquired developed technologies) 148,917 127,930 121,544 110,188 105,386
−Removed: Selling, general and administrative 854,233 736,942 683,530 544,156 502,892
−Removed: Research and development 335,375 299,726 226,616 198,442 162,297
−Removed: Intangible asset amortization 259,580 354,814 201,498 152,065 101,994
−Removed: Impairment charges 136,139 — 42,896 — —
−Removed: Acquired in-process research and development 251,250 109,975 — 85,000 23,750
−Removed: Total operating expenses 1,985,494 1,629,387 1,276,084 1,089,851 896,319
−Removed: Income from operations 378,073 532,374 614,838 528,842 591,654
−Removed: Interest expense, net (99,707) (72,261) (78,500) (77,756) (62,580)
−Removed: Foreign exchange gain (loss) (3,271) (5,811) (6,875) (9,969) 3,372
−Removed: Income before income tax provision (benefit) and equity in loss of investees 275,095 454,302 529,463 441,117 532,446
−Removed: Income tax provision (benefit) 33,517 (73,154) 80,162 (47,740) 135,236
−Removed: Equity in loss of investees 2,962 4,089 2,203 1,009 379
−Removed: Net income $ 238,616 $ 523,367 $ 447,098 $ 487,848 $ 396,831
−Removed: Net income per ordinary share:
−Removed: Basic $ 4.28 $ 9.22 $ 7.45 $ 8.13 $ 6.56
−Removed: Diluted $ 4.22 $ 9.09 $ 7.30 $ 7.96 $ 6.41
−Removed: Weighted-average ordinary shares used in per share calculations - basic 55,712 56,749 59,976 60,018 60,500
−Removed: Weighted-average ordinary shares used in per share calculations - diluted 56,517 57,550 61,221 61,317 61,870
−Removed: As of December 31,
−Removed: 2020 2019 2018 2017 2016(1)
−Removed: (In thousands)
−Removed: Consolidated Balance Sheet Data:
−Removed: Cash, cash equivalents and investments $ 2,132,769 $ 1,077,344 $ 824,622 $ 601,035 $ 425,963
−Removed: Working capital 2,185,823 1,265,778 888,518 674,330 490,663
−Removed: Total assets 6,535,901 5,538,897 5,203,491 5,123,672 4,800,227
−Removed: Long-term debt, current and non-current 2,094,838 1,607,257 1,596,412 1,581,038 2,029,625
−Removed: Retained earnings 1,159,894 1,067,815 841,050 917,956 528,907
−Removed: Total Jazz Pharmaceuticals plc shareholders’ equity 3,659,745 3,110,981 2,757,422 2,713,097 1,877,339
−Removed: __________________________
−Removed: (1) On July 12, 2016, we completed the acquisition of Celator Pharmaceuticals, Inc., or Celator, which acquisition we refer to in this report as the Celator Acquisition, for an aggregate cash consideration of $1.5 billion and the results of operations of the acquired Celator business, along with the estimated fair values of the assets acquired and liabilities assumed, have been included in our consolidated financial statements since the closing of the Celator Acquisition.
+Added: Under the share repurchase program, we are authorized to repurchase shares from time to time through open market repurchases.
+Added: Such repurchases may be pursuant to Rule 10b-18 or Rule 10b5-1 agreements as determined by our management and in accordance with the requirements of the Securities and Exchange Commission.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.